West Pharmaceutical Services, Inc. (FRA:WPS)
Germany · Delayed Price · Currency is EUR | Market Cap | 19.23B +37.7% |
| Revenue (ttm) | 2.79B +11.2% |
| Net Income | 470.68M +16.2% |
| EPS | 6.49 +17.4% |
| Shares Out | n/a |
| PE Ratio | 40.86 |
| Forward PE | 36.14 |
| Dividend | 0.74 (0.28%) |
| Ex-Dividend Date | Apr 29, 2026 |
| Volume | n/a |
| Open | 266.50 |
| Previous Close | 269.10 |
| Day's Range | 266.50 - 266.50 |
| 52-Week Range | 178.35 - 275.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About FRA:WPS
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more]
Financial Performance
In 2025, FRA:WPS's revenue was $3.07 billion, an increase of 6.25% compared to the previous year's $2.89 billion. Earnings were $493.70 million, an increase of 0.20%.
Financial numbers in USD Financial StatementsNews
West Pharmaceutical Services Transcript: 46th Annual William Blair Growth Stock Conference
Strong growth in high-value injectable medicine components, driven by biologics, GLP-1s, and regulatory changes, is fueling double-digit margin and EPS expansion. Leadership transition to a new CEO aligns with strategic growth, supported by robust cash flow and global market presence.
West Pharmaceutical Services Slides: 46th Annual William Blair Growth Stock Conference
West Pharmaceutical Services has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
West Pharma names former Thermo Fisher executive Lagarde as CEO
West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel Lagarde as its top boss, effective August 31, succeeding longtime chief Eric Green.
West Pharmaceutical says Michel Lagarde to succeed Eric Green as CEO
West Pharmaceutical (WST) Services announced that its Board of Directors has appointed Michel Lagarde to be President and CEO and a member of the company’s Board of Directors starting August…
West Pharmaceutical assumed with Outperform at Wolfe Research
As previously reported, Wolfe Research analyst Mike Polark upgraded West Pharmaceutical (WST) to Outperform from Peer Perform with a $375 price target Q1 was “juicy good,” driven by continued GLP1…
West Appoints Michel Lagarde to be President and Chief Executive Officer
Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a ...
West Pharmaceutical assumed at Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded West Pharmaceutical (WST) to Outperform from Peer Perform as the analyst assumed coverage of the stock.
West Pharmaceutical price target raised to $325 from $315 at Morgan Stanley
Morgan Stanley raised the firm’s price target on West Pharmaceutical (WST) to $325 from $315 and keeps an Equal Weight rating on the shares after having hosted members of West’s…
West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast
West Pharmaceutical Services said on Wednesday it has restored operations across its sites after a cybersecurity attack earlier this month and expects the incident to have no material impact on its ...
West Pharma says operations recovering after cyberattack
West Pharmaceutical Services said on Friday its operations were steadily recovering after a cyberattack earlier this month disrupted manufacturing and logistics globally.
West Pharmaceutical reports ‘significant progress’ in post-cyberattack recovery
West Pharmaceutical (WST) provided a cyberattack update, saying the company continues to make significant progress in restoring its operations globally. Regarding the proprietary products segment, Wes...
West Pharmaceutical Services Transcript: Bank of America Global Healthcare Conference 2026
A recent cybersecurity breach was contained with minimal disruption, and operations are being restored methodically. Strong Q1 results were driven by robust demand for HVP components, GLP-1s, and regulatory changes, supporting raised guidance and long-term growth expectations.
West Pharmaceutical Services Transcript: AGM 2026
The meeting covered board elections, executive compensation, auditor ratification, and a shareholder proposal for an independent board chair, which was not approved. All director nominees were reelected and executive pay was endorsed by a majority.
West to Participate in Upcoming Investor Conferences
EXTON, Pa., April 28, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will pres...
West Pharmaceutical price target raised to $315 from $285 at Morgan Stanley
Morgan Stanley raised the firm’s price target on West Pharmaceutical (WST) to $315 from $285 and keeps an Equal Weight rating on the shares.
West Pharmaceutical price target raised to $310 from $275 at Barclays
Barclays raised the firm’s price target on West Pharmaceutical (WST) to $310 from $275 and keeps an Equal Weight rating on the shares. The firm updated the company’s model following…
West Pharmaceutical price target raised to $400 from $375 at Citi
Citi raised the firm’s price target on West Pharmaceutical (WST) to $400 from $375 and keeps a Buy rating on the shares.
West Pharmaceutical price target raised to $390 from $320 at Evercore ISI
Evercore ISI raised the firm’s price target on West Pharmaceutical (WST) to $390 from $320 and keeps an Outperform rating on the shares.
West Pharmaceutical Services Earnings Call Transcript: Q1 2026
Q1 2026 delivered 21% revenue growth and 47% higher adjusted EPS, driven by strong HVP component and biologics demand. Full-year guidance was raised for both revenue and EPS, with operational excellence and global regulatory trends supporting continued momentum.
West Pharmaceutical Services Slides: Q1 2026
West Pharmaceutical Services has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
West Pharmaceutical Services Earnings release: Q1 2026
West Pharmaceutical Services released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
West Pharmaceutical Services Quarterly report: Q1 2026
West Pharmaceutical Services has published its Q1 2026 quarterly earnings report on April 23, 2026.
West Pharma lifts 2026 profit forecast on strong demand for medical equipment
West Pharmaceutical on Thursday raised its annual profit and revenue forecasts after beating estimates for first-quarter results, betting on strong demand for its proprietary products that include sy...
West Reports First-Quarter 2026 Results
Strong Start to the Year and Raising Full-Year Revenue and EPS guidance EXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, hig...
West Pharmaceutical price target raised to $275 from $265 at Barclays
Barclays raised the firm’s price target on West Pharmaceutical (WST) to $275 from $265 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the life…